Literature DB >> 2953388

Topical provocation of fixed drug eruption.

K Alanko, S Stubb, S Reitamo.   

Abstract

To determine whether topical provocation could be used for the diagnosis of fixed drug eruption (FDE) instead of systemic provocation, we applied the suspected drug at various concentrations (1-10%) in either petrolatum, 94% ethanol or dimethyl sulphoxide (DMSO) as an open test on both clinically normal skin and on previous FDE lesions in 24 patients with established FDE due to phenazone salicylate, a sulphonamide, doxycycline, trimethoprim, chlormezanone, a barbiturate, or carbamazepine. In 18 of the 24 patients, local provocation of FDE was seen at sites or previous eruption but never on clinically normal skin. With some drugs, e.g. phenazone salicylate, positive provocation of FDE was seen with all the vehicles used; with sulphamethoxazole and trimethoprim, a positive result was seen only in DMSO. To study cross-reactions to other phenazone derivatives in patients with an FDE caused by phenazone salicylate, we applied topical phenazone, aminophenazone and propyphenazone to sites of previous FDE lesions in three patients. In all three, a positive reaction was seen with phenazone, but only one patient showed positive results with aminophenazone and propyphenazone. The present study suggests that topical provocation is useful with several drugs causing FDE. Testing should always be performed on sites of previous FDE, and the sensitivity of the open topical testing can be increased in certain cases by using a vehicle which increases penetration of the drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953388     DOI: 10.1111/j.1365-2133.1987.tb05879.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

1.  Fluconazole-induced Fixed Drug Eruption.

Authors:  Cory Allen Gaiser; Dominick Sabatino
Journal:  J Clin Aesthet Dermatol       Date:  2013-03

Review 2.  Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 3.  Management of cutaneous drug reactions.

Authors:  K S Babu; Geeta Belgi
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.919

4.  Fixed drug eruption induced by atenolol.

Authors:  H Belhadjali; O Trimech; M Youssef; I Elhani; J Zili
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-24

5.  Clinical Management of Nonsteroidal Anti-inflammatory Drug Hypersensitivity.

Authors:  Mario Sánchez-Borges
Journal:  World Allergy Organ J       Date:  2008-02       Impact factor: 4.084

6.  Skin testing and patch testing in non-IgE-mediated drug allergy.

Authors:  Annick Barbaud
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.919

7.  Stamping a Case of Cutaneous Adverse Drug Reaction: Proving Beyond Causality Assessment.

Authors:  Sudip Das; Projna Biswas; Dayamay Pal; Abhishek De
Journal:  Indian J Dermatol       Date:  2018 Mar-Apr       Impact factor: 1.494

Review 8.  The Role of Patch Testing in Evaluating Delayed Hypersensitivity Reactions to Medications.

Authors:  Carina M Woodruff; Nina Botto
Journal:  Clin Rev Allergy Immunol       Date:  2022-02-03       Impact factor: 10.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.